MX2022012079A - Metodos y composiciones para mantener la salud renal. - Google Patents

Metodos y composiciones para mantener la salud renal.

Info

Publication number
MX2022012079A
MX2022012079A MX2022012079A MX2022012079A MX2022012079A MX 2022012079 A MX2022012079 A MX 2022012079A MX 2022012079 A MX2022012079 A MX 2022012079A MX 2022012079 A MX2022012079 A MX 2022012079A MX 2022012079 A MX2022012079 A MX 2022012079A
Authority
MX
Mexico
Prior art keywords
agents
compositions
methods
health
conditions
Prior art date
Application number
MX2022012079A
Other languages
English (en)
Inventor
Thomas Weimbs
Jacob Torres
Muthusamy Thangaraju
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2022012079A publication Critical patent/MX2022012079A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones y métodos para mantener la salud, especialmente la salud renal, que comprenden agentes cetónicos que recapitulan los efectos beneficiosos de la cetosis mediante agentes administrados exógenamente. Los agentes incluyen BHB, sus análogos y agonistas de GPR109A. Los agentes pueden incluir, además, inhibidores de la precipitación de cristales que mejoran sinérgicamente el tratamiento de ciertas afecciones renales. Los agentes pueden usarse en suplementos dietéticos y composiciones terapéuticas para el tratamiento de enfermedades renales quísticas tales como la enfermedad renal poliquística, ciliopatías y otras afecciones.
MX2022012079A 2019-03-14 2021-09-14 Metodos y composiciones para mantener la salud renal. MX2022012079A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962818538P 2019-03-14 2019-03-14

Publications (1)

Publication Number Publication Date
MX2022012079A true MX2022012079A (es) 2022-10-18

Family

ID=72423085

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021011222A MX2021011222A (es) 2019-03-14 2020-03-13 Métodos y composiciones para mantener la salud renal.
MX2022012079A MX2022012079A (es) 2019-03-14 2021-09-14 Metodos y composiciones para mantener la salud renal.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021011222A MX2021011222A (es) 2019-03-14 2020-03-13 Métodos y composiciones para mantener la salud renal.

Country Status (7)

Country Link
US (3) US11013705B2 (es)
EP (1) EP3937920A4 (es)
CN (1) CN114144174A (es)
AU (1) AU2020235643A1 (es)
CA (1) CA3129569A1 (es)
MX (2) MX2021011222A (es)
WO (1) WO2020186154A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
WO2022173813A1 (en) * 2021-02-09 2022-08-18 The Regents Of The University Of California Improved bhb-citrate formulations for promoting health
US20210252045A1 (en) * 2019-12-11 2021-08-19 John I. Toohey Method for inactivating and removing disease-related levels of sulfane sulfur from affected biological tissues with special relevance to Covid-19 virus infection
US20230119628A1 (en) * 2020-03-27 2023-04-20 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid -19 and related viral infections
RU2763933C1 (ru) * 2020-12-24 2022-01-11 Юлия Викторовна Мукий Тест-система для выявления мутации в гене btpkd собаки домашней (canis lupus familiaris), вызывающей поликистоз почек
EP4366720A1 (en) * 2021-07-09 2024-05-15 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
US20240065991A1 (en) * 2022-08-26 2024-02-29 Health Via Modern Nutrition Inc. Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777170A (en) * 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
WO1995009144A1 (en) 1993-09-30 1995-04-06 Eastman Chemical Company Nutritive water soluble glycerol esters of hydroxy butyric acid
EP1146075A1 (de) * 2000-04-10 2001-10-17 Alusuisse Martinswerk GmbH Verfahren zur Herstellung von Füllstoffen mit verbesserter Schüttdichtestabilität und Rieselfähigkeit
JP5114631B2 (ja) * 2003-09-01 2013-01-09 有限会社アーザス β−ヒドロキシ短〜中鎖脂肪酸重合体
US20060083727A1 (en) * 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
US20090247589A1 (en) * 2006-09-14 2009-10-01 The Brigham And Women's Hospital, Inc. Monocarboxylates for modifying macrophage function
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia
US9744152B2 (en) * 2010-07-19 2017-08-29 Ic-Medtech Corporation Vitamins C and K for treating polycystic diseases
MY180761A (en) * 2013-03-19 2020-12-08 Univ South Florida Compositions and methods for producing elevated and sustained ketosis
US10285961B2 (en) * 2014-02-06 2019-05-14 University Of Houston System Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof
CN104464625B (zh) 2014-12-10 2016-09-21 合肥鑫晟光电科技有限公司 像素电路及其驱动方法、阵列基板、显示装置
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
WO2018187852A1 (en) * 2017-04-12 2018-10-18 Cavaleri Franco Butyrate and beta-hydroxybutyrate compositions and methods of use thereof
EP3398600A1 (en) 2017-05-02 2018-11-07 Salmon Pharma GmbH Modified release nicotinamide
BR112020001285A2 (pt) * 2017-07-21 2020-07-28 Buck Institute For Research On Aging s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização
CN107536035A (zh) * 2017-08-14 2018-01-05 迈德同信（武汉）科技股份有限公司 一种含酮的功能食品及其用途
BR112020004053A2 (pt) 2017-08-31 2020-09-01 Lonza Llc composição de promoção da saúde e métodos de uso de suplementos
US20190262415A1 (en) * 2018-02-26 2019-08-29 Ketologie LLC Supplement for inducing and sustaining nutritional ketosis

Also Published As

Publication number Publication date
US20210244695A1 (en) 2021-08-12
CN114144174A (zh) 2022-03-04
US20210244694A1 (en) 2021-08-12
EP3937920A4 (en) 2022-12-14
CA3129569A1 (en) 2020-09-17
US11013705B2 (en) 2021-05-25
US20200289444A1 (en) 2020-09-17
WO2020186154A1 (en) 2020-09-17
EP3937920A1 (en) 2022-01-19
AU2020235643A1 (en) 2021-09-30
MX2021011222A (es) 2022-09-28

Similar Documents

Publication Publication Date Title
MX2022012079A (es) Metodos y composiciones para mantener la salud renal.
NZ729290A (en) Composition containing a mixture of plant extracts or a mixture of molecules contained in said plants, and use for controlling carbohydrate and/or lipid metabolism
MA41197B1 (fr) Traitement de le pemphigus
MX2009011898A (es) Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
MX338247B (es) Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
MX2022009942A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
PH12016502100A1 (en) Liquid formulation comprising gm-csf neutralizing compound
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
SG10201906400SA (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EA201891651A3 (ru) Фармацевтическая композиция для профилактики алиментарного ожирения
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
MX2023003348A (es) Compuestos y composiciones como moduladores de señalización tlr.
MX2022004382A (es) Metodos para promover la produccion de scfa por microbiota intestinal.
ZA202002103B (en) Compounds as mpges-1 inhibitors
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
MX2020009629A (es) Una composición para su uso en el tratamiento de afecciones provocadas por la carencia de calcio.
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MA44769B1 (fr) Formulations destinées à une utilisation dans le traitement ou la prévention de maladies urologiques
MD1375Y (ro) Metodă de tratament al afecţiunilor inflamatorii ale ţesuturilor moi şi articulaţiilor
MX2021005669A (es) Metodos para mejorar la salud metabolica en un animal.